Regen BioPharma Inc. announced today submission of a proposed experimental protocol to the FDA as part of ongoing discussions regarding initiation of a 10 patient aplastic anemia clinical trial utilizing the company's personalized adipose stem cell based therapy, HemaXellerate. The protocol submission was the result of a telephonic meeting with FDA officials, in which the Agency permitted the Company to provide additional input on preclinical safety experiments that need to be conducted before the clinical trial is initiated.
http://ift.tt/1tGVkL9
http://ift.tt/1tGVkL9
No comments:
Post a Comment